{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:19Z","timestamp":1790205499281,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Paraoxonase 1 (PON1) phenotype is a better predictor of atherosclerosis risk than are PON1 genetic polymorphisms alone. Larger studies are required to determine the role of PON1 and there is a need for standardized PON1 assays between laboratories.<\/jats:p>\n               <jats:p>Methods: We have adapted 5 enzyme kinetic assays for high-throughput automated analysis of PON1 activity. Using different substrates and reaction conditions, we measured PON1 activity and used activity ratios to identify the PON1 Q192R genetic polymorphisms and assessed the accuracy of the genotype assignments in 79 adult study participants by comparing them with genotypes determined by AlwI restriction enzyme digestion of a 176-bp PCR amplification product from genomic DNA. Imprecision was determined using pooled serum and purified enzyme preparations. Biological variability was estimated by analysis of serial samples from 17 individuals. Variability parameters were compared with total cholesterol as a point of reference to a recognized biomarker of coronary heart disease risk.<\/jats:p>\n               <jats:p>Results: Salt stimulation and inhibition ratios were 97.4% and 94.7% correct in assigning Q192R genotype, respectively. Analytical imprecision (CV) was 1.0%\u20133.0% for phenylacetate and paraoxon substrate assays and 3.0%\u20138.0% for the para-nitrophenylacetate substrate assays. Combination of the 2 ratios into a double ratio resulted in 100% correct genotype classification.<\/jats:p>\n               <jats:p>Conclusion: The described methods for measurement of PON1 activity and accurate genotype assignment are rapid and have potential to facilitate the efficient investigation of PON1 status in clinical and epidemiological studies.<\/jats:p>","DOI":"10.1373\/clinchem.2006.074559","type":"journal-article","created":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T20:29:29Z","timestamp":1166732969000},"page":"310-317","source":"Crossref","is-referenced-by-count":84,"title":["Accuracy and Biological Variation of Human Serum Paraoxonase 1 Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay"],"prefix":"10.1093","volume":"53","author":[{"given":"Richard W","family":"Browne","sequence":"first","affiliation":[{"name":"Departments of Biotechnical and Clinical Laboratory Sciences, State University of New York at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T","family":"Koury","sequence":"first","affiliation":[{"name":"Departments of Biotechnical and Clinical Laboratory Sciences, State University of New York at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Marion","sequence":"first","affiliation":[{"name":"Departments of Biotechnical and Clinical Laboratory Sciences, State University of New York at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Wilding","sequence":"first","affiliation":[{"name":"Departments of Biostatistics, State University of New York at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Muti","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Italian National Cancer Institute \u201cRegina Elena\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Trevisan","sequence":"first","affiliation":[{"name":"Departments of Social and Preventive Medicine, State University of New York at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"2020022802442813600_R1","doi-asserted-by":"crossref","unstructured":"Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol2005;69:541-550.","DOI":"10.1016\/j.bcp.2004.08.027"},{"key":"2020022802442813600_R2","doi-asserted-by":"crossref","unstructured":"Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J1993;294:829-834.","DOI":"10.1042\/bj2940829"},{"key":"2020022802442813600_R3","doi-asserted-by":"crossref","unstructured":"Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet1999;353:468-469.","DOI":"10.1016\/S0140-6736(98)05105-8"},{"key":"2020022802442813600_R4","doi-asserted-by":"crossref","unstructured":"Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters1998;423:57-60.","DOI":"10.1016\/S0014-5793(98)00064-7"},{"key":"2020022802442813600_R5","doi-asserted-by":"crossref","unstructured":"Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest1995;96:2882-2891.","DOI":"10.1172\/JCI118359"},{"key":"2020022802442813600_R6","doi-asserted-by":"crossref","unstructured":"Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest1998;101:1581-1590.","DOI":"10.1172\/JCI1649"},{"key":"2020022802442813600_R7","doi-asserted-by":"crossref","unstructured":"Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet1993;3:73-76.","DOI":"10.1038\/ng0193-73"},{"key":"2020022802442813600_R8","doi-asserted-by":"crossref","unstructured":"Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet1996;14:334-336.","DOI":"10.1038\/ng1196-334"},{"key":"2020022802442813600_R9","doi-asserted-by":"crossref","unstructured":"Serrato M, Marian AJ. A variant human paraoxonase\/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest1995;96:3005-3008.","DOI":"10.1172\/JCI118373"},{"key":"2020022802442813600_R10","doi-asserted-by":"crossref","unstructured":"Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol1997;17:1067-1073.","DOI":"10.1161\/01.ATV.17.6.1067"},{"key":"2020022802442813600_R11","doi-asserted-by":"crossref","unstructured":"Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet1998;62:36-44.","DOI":"10.1086\/301669"},{"key":"2020022802442813600_R12","doi-asserted-by":"crossref","unstructured":"Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol1997;17:3565-3569.","DOI":"10.1161\/01.ATV.17.12.3565"},{"key":"2020022802442813600_R13","doi-asserted-by":"crossref","unstructured":"Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, et al. Paraoxonase. Gln\/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes1999;192(48):623-627.","DOI":"10.2337\/diabetes.48.3.623"},{"key":"2020022802442813600_R14","doi-asserted-by":"crossref","unstructured":"Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol1998;66:165-168.","DOI":"10.1016\/S0167-5273(98)00209-5"},{"key":"2020022802442813600_R15","doi-asserted-by":"crossref","unstructured":"Ruiz J, Blanche H, James RW, Blatter-Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet1995;346:869-872.","DOI":"10.1016\/S0140-6736(95)92709-3"},{"key":"2020022802442813600_R16","doi-asserted-by":"crossref","unstructured":"Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab1997;82:2257-2260.","DOI":"10.1210\/jcem.82.7.4096"},{"key":"2020022802442813600_R17","doi-asserted-by":"crossref","unstructured":"Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahhvanainen E, Jauhiainen M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest1996;98:883-885.","DOI":"10.1172\/JCI118869"},{"key":"2020022802442813600_R18","doi-asserted-by":"crossref","unstructured":"Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol1996;57:69-73.","DOI":"10.1016\/S0167-5273(96)02779-9"},{"key":"2020022802442813600_R19","doi-asserted-by":"crossref","unstructured":"Herrmann S-M, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, et al. The Gln\/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis1996;126:299-303.","DOI":"10.1016\/0021-9150(96)05917-5"},{"key":"2020022802442813600_R20","doi-asserted-by":"crossref","unstructured":"Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol1998;18:1611-1616.","DOI":"10.1161\/01.ATV.18.10.1611"},{"key":"2020022802442813600_R21","doi-asserted-by":"crossref","unstructured":"Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol2001;21:1451-1457.","DOI":"10.1161\/hq0901.094247"},{"key":"2020022802442813600_R22","doi-asserted-by":"crossref","unstructured":"Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol1999;19:330-335.","DOI":"10.1161\/01.ATV.19.2.330"},{"key":"2020022802442813600_R23","unstructured":"Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet1983;35:214-227."},{"key":"2020022802442813600_R24","unstructured":"Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase\/arylesterase polymorphism. Am J Hum Genet1983;35:1126-1138."},{"key":"2020022802442813600_R25","unstructured":"La Du BN, Piko JI, Eckerson HW, Vincent-Viry M, Siest G. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. Ann Biol Clin1986;44:369-372."},{"key":"2020022802442813600_R26","doi-asserted-by":"crossref","unstructured":"Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem1992;30:391-395.","DOI":"10.1515\/cclm.1992.30.7.391"},{"key":"2020022802442813600_R27","unstructured":"Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new assay, population, family, biochemical, and linkage studies. Am J Hum Genet1983;35:393-408."},{"key":"2020022802442813600_R28","doi-asserted-by":"crossref","unstructured":"Richter RJ. Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics1999;9:745-753.","DOI":"10.1097\/00008571-199912000-00009"},{"key":"2020022802442813600_R29","doi-asserted-by":"crossref","unstructured":"Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem;52:453-457.","DOI":"10.1373\/clinchem.2005.063412"},{"key":"2020022802442813600_R30","doi-asserted-by":"crossref","unstructured":"Murphy JM, Browne RW, Hill L, Bolelli GF, Abagnato C, Berrino F, et al. Effects of transportation and delay in processing on the stability of nutritional and metabolic biomarkers. Nutr Cancer2000;37:155-160.","DOI":"10.1207\/S15327914NC372_6"},{"key":"2020022802442813600_R31","unstructured":"Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase\/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos1991;19:100-106."},{"key":"2020022802442813600_R32","doi-asserted-by":"crossref","unstructured":"Fraser CG, Hyltoft Petersen P, Libeer JC, Ricos C. Proposals for setting generally applicable quality goals solely based on biology. Ann Clin Biochem1997;34:8-12.","DOI":"10.1177\/000456329703400103"},{"key":"2020022802442813600_R33","doi-asserted-by":"crossref","unstructured":"Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?. Free Radic Biol Med2004;37:1317-1323.","DOI":"10.1016\/j.freeradbiomed.2004.07.034"},{"key":"2020022802442813600_R34","doi-asserted-by":"crossref","unstructured":"Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. CRC Crit Rev Clin Lab Sci1989;:409-437.","DOI":"10.3109\/10408368909106595"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/2\/310\/32689114\/clinchem0310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/2\/310\/32689114\/clinchem0310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T02:46:24Z","timestamp":1582857984000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/53\/2\/310\/5627281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,2,1]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.074559","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,2,1]]},"published":{"date-parts":[[2007,2,1]]}}}